表紙
市場調査レポート

治療抵抗性鬱病:パイプライン製品の分析

Treatment Resistant Depression - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 302486
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
治療抵抗性鬱病:パイプライン製品の分析 Treatment Resistant Depression - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 64 Pages
概要

治療抵抗性鬱病(TRD)は、抗鬱剤が効かない、大鬱病性障害の発作です。集中力の欠如、疲労、不眠症、過食や食欲不振、持続的な痛み、頭痛、けいれん、消化器の異常などの症状が生じます。

当レポートでは、治療抵抗性鬱病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

治療抵抗性鬱病の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

治療抵抗性鬱病:企業で開発中の治療薬

治療抵抗性鬱病:大学/機関で研究中の治療薬

治療抵抗性鬱病:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

治療抵抗性鬱病:企業で開発中の製品

治療抵抗性鬱病:大学/機関で研究中の製品

治療抵抗性鬱病の治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Axsome Therapeutics, Inc.
  • Johnson & Johnson
  • 大塚ホールディングス

治療抵抗性鬱病:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

治療抵抗性鬱病:最近のパイプライン動向

治療抵抗性鬱病:休止中のプロジェクト

治療抵抗性鬱病:開発が中止された製品

治療抵抗性鬱病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7889IDB

Summary

Global Markets Direct's, 'Treatment Resistant Depression - Pipeline Review, H1 2016', provides an overview of the Treatment Resistant Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression
  • The report reviews pipeline therapeutics for Treatment Resistant Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Treatment Resistant Depression therapeutics and enlists all their major and minor projects
  • The report assesses Treatment Resistant Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Treatment Resistant Depression

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Treatment Resistant Depression
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Treatment Resistant Depression pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Treatment Resistant Depression Overview
  • Therapeutics Development
    • Pipeline Products for Treatment Resistant Depression - Overview
    • Pipeline Products for Treatment Resistant Depression - Comparative Analysis
  • Treatment Resistant Depression - Therapeutics under Development by Companies
  • Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes
  • Treatment Resistant Depression - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Treatment Resistant Depression - Products under Development by Companies
  • Treatment Resistant Depression - Products under Investigation by Universities/Institutes
  • Treatment Resistant Depression - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Amorsa Therapeutics Inc.
    • Axsome Therapeutics, Inc.
    • Johnson & Johnson
    • Otsuka Holdings Co., Ltd.
  • Treatment Resistant Depression - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (dextromethorphan + quinidine sulfate) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMS-410 FA - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMS-520 ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVP-786 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • esketamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-100 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • riluzole - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VU-0431316 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Treatment Resistant Depression - Recent Pipeline Updates
  • Treatment Resistant Depression - Dormant Projects
  • Treatment Resistant Depression - Discontinued Products
  • Treatment Resistant Depression - Product Development Milestones
    • Featured News & Press Releases
      • Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression
      • Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
      • Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Treatment Resistant Depression, H1 2016
  • Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Treatment Resistant Depression - Pipeline by Amorsa Therapeutics Inc., H1 2016
  • Treatment Resistant Depression - Pipeline by Axsome Therapeutics, Inc., H1 2016
  • Treatment Resistant Depression - Pipeline by Johnson & Johnson, H1 2016
  • Treatment Resistant Depression - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Treatment Resistant Depression Therapeutics - Recent Pipeline Updates, H1 2016
  • Treatment Resistant Depression - Dormant Projects, H1 2016
  • Treatment Resistant Depression - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Treatment Resistant Depression, H1 2016
  • Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top